UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
Thiophenes - adverse effects | Humans | Middle Aged | Body Weight - drug effects | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Double-Blind Method | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Glycemic index | Dosage and administration | Metformin | Prescription drugs | Blood pressure | Diabetes | Patients | Weight | Index Medicus
Journal Article
International journal of clinical practice (Esher), ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
Medicine, General & Internal | Pharmacology & Pharmacy | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Index Medicus | Endocrinology
Journal Article
The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 01/2016, Volume 101, Issue 1, pp. 157 - 166
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Age Factors | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Fractures, Bone - epidemiology | Male | Risk | Canagliflozin - adverse effects | Incidence | Dose-Response Relationship, Drug | Cardiovascular Diseases - complications | Canagliflozin - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Accidental Falls | Diabetes Mellitus, Type 2 - complications | Diuretics - adverse effects | Index Medicus | Abridged Index Medicus | Original
Journal Article
Nature reviews. Nephrology, ISSN 1759-5061, 08/2018, Volume 14, Issue 8, pp. 473 - 474
Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Bone Demineralization, Pathologic - chemically induced | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Bone Density - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Fibroblast Growth Factors - blood | Phosphorus - blood | Humans | Vitamin D - analogs & derivatives | Canagliflozin - adverse effects | Parathyroid Hormone - blood | Fractures, Bone - chemically induced | Vitamin D - blood | Osteoporosis | Bones | Research | Health aspects | Risk factors | Side effects | Inhibitor drugs | Vitamin D | Index Medicus
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2018, Volume 67, Issue 6, pp. 1182 - 1189
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Gluconeogenesis - drug effects | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucagon - antagonists & inhibitors | Glucagon - agonists | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Secreting Cells - drug effects | Insulin-Secreting Cells - metabolism | Canagliflozin - therapeutic use | Glucagon-Secreting Cells - metabolism | Adult | Female | Hypoglycemia - chemically induced | Insulin Secretion | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Reproducibility of Results | Insulin - agonists | Sodium-Glucose Transporter 2 - metabolism | Sodium-Glucose Transporter 2 Inhibitors | Canagliflozin - adverse effects | Down-Regulation - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Insulin - chemistry | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Liraglutide | Glucagon | Cardiomyopathy | Diabetes mellitus | Clinical trials | Diabetes | Glucose | Epidemiology | Diabetes mellitus (non-insulin dependent) | Insulin | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
METFORMIN | GLYCEMIC CONTROL | PLACEBO | MONOTHERAPY | SULFONYLUREA | SITAGLIPTIN | DOUBLE-BLIND | RANDOMIZED-TRIAL | POOLED ANALYSIS | MELLITUS | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycosuria - chemically induced | Hypovolemia - chemically induced | Thiophenes - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Glucosides - adverse effects | Double-Blind Method | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Mycoses - chemically induced | Clinical trials | Prescription drugs | Diabetes | Safety | Drug therapy | Index Medicus
Journal Article
Current medical research and opinion, ISSN 0300-7995, 2/2014, Volume 30, Issue 2, pp. 163 - 175
Glycemic control | Body weight reduction | Sodium glucose co-transporter 2 (SGLT2) inhibitor | Phase 3 study | Type 2 diabetes mellitus | Canagliflozin | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Thiophenes - therapeutic use | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Body Weight - drug effects | Male | Pyrazines - therapeutic use | Weight Loss - drug effects | Exercise | Cholesterol, LDL - blood | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Sitagliptin Phosphate | Hypoglycemia - chemically induced | Glucosides - adverse effects | Placebos - administration & dosage | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Blood Glucose | Sodium-Glucose Transporter 2 Inhibitors | Treatment Outcome | Diet | Pyrazines - adverse effects | Triglycerides - blood | Cholesterol, HDL - blood | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Index Medicus
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 01/2015, Volume 75, Issue 1, pp. 33 - 59
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Glucosides - pharmacology | Thiophenes - adverse effects | Humans | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Benzhydryl Compounds - adverse effects | Canagliflozin | Glucosides - therapeutic use | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects
Journal Article
Metabolism, clinical and experimental, ISSN 0026-0495, 07/2019, Volume 96, pp. 92 - 100
Empagliflozin | Canagliflozin | Dapagliflozin | Sodium-glucose co-transporter-2 inhibitors | Amputation | Cardiovascular risk | Renal outcomes | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Benzhydryl Compounds - adverse effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Risk Assessment | Humans | Amputation - statistics & numerical data | Canagliflozin - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Glucose | Dextrose | Index Medicus
Journal Article